Grant: Collaborative Health Research Projects
University of Ottawa
$87,905.00
Cocooning Therapeutic Cells
EF 2015-16
Résumé
Medical therapies using undifferentiated cells (stem and progenitor) are emerging and are defining a new era in regenerative
medicine. Our proposed research study targets the development of a cell encapsulation process for delivery to patients
suffering from severe life-threatening disorders. Specifically, we are working with Northern Therapeutics, a Canadian
biotechnology company that has developed new and effective autologous cell therapies for pulmonary diseases. A
fundamental limitation to new cell therapies is the currently cumbersome cell pre-conditioning process that limits the
widespread commercialization of their technology. To address this unmet and critical cell processing need, we have
assembled a team of researchers from both physics and the life sciences to develop a scalable microfluidics-based stem cell
encapsulation procedure that will allow for the rapid and reproducible manufacture of single-cell capsules. These capsules
will be supplemented with novel biomimetic matrices that include bionanoparticles specifically designed to enhance cell
function and organ-specific engraftment, and this way enhance the therapeutic effect of the cells. If successful this research
will be widely applicable to the field of regenerative medicine, be of marked benefit to chronically ill patients, aide in the
global competitiveness of a Canadian company, and stimulate economic development in Canada in an emerging new
market.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
478517-2015
Name nom
Godin, Michel
Department département
Physics
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
87905
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Cocooning Therapeutic Cells
Keyword
NSERC
Application summary
Medical therapies using undifferentiated cells (stem and progenitor) are emerging and are defining a new era in regenerative
medicine. Our proposed research study targets the development of a cell encapsulation process for delivery to patients
suffering from severe life-threatening disorders. Specifically, we are working with Northern Therapeutics, a Canadian
biotechnology company that has developed new and effective autologous cell therapies for pulmonary diseases. A
fundamental limitation to new cell therapies is the currently cumbersome cell pre-conditioning process that limits the
widespread commercialization of their technology. To address this unmet and critical cell processing need, we have
assembled a team of researchers from both physics and the life sciences to develop a scalable microfluidics-based stem cell
encapsulation procedure that will allow for the rapid and reproducible manufacture of single-cell capsules. These capsules
will be supplemented with novel biomimetic matrices that include bionanoparticles specifically designed to enhance cell
function and organ-specific engraftment, and this way enhance the therapeutic effect of the cells. If successful this research
will be widely applicable to the field of regenerative medicine, be of marked benefit to chronically ill patients, aide in the
global competitiveness of a Canadian company, and stimulate economic development in Canada in an emerging new
market.